Recent studies have shown that high peak enhancement is correlated with low tumor-infiltrating lymphocytes (TIL) levels in HER2-positive tumors, and although the association is not statistically significant, a similar trend has been observed in TNBC [35,36]. The gene discussed is ERBB2; the disease is neoplasm.